Lymphoma, T-Cell, Peripheral
A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.
Drugs by status
Approved for this indication (3)
Phase 4 trials (13)
Phase 3 trials (16)
Phase 2 trials (88)
- azacitidine
- methylprednisolone
- afm13
- alrn-6924
- Gusacitinib
- sorafenib
- bendamustine
- brentuximab vedotin
- busulfan
- carfilzomib
- clofarabine
- denileukin diftitox
- duvelisib
- n-(4-hydroxyphenyl)all-trans retinamide
- folic acid
- tacrolimus
- naltrexone
- lapatinib
- aldesleukin
- cyanocobalamin
- epirubicin
- nivolumab
- iph4102
- ixazomib
- pembrolizumab
- msk-2206
- navitoclax
- panobinostat
- pegaspargase
- pentostatin
- +58 more
Phase 1 trials (45)
- dexrazoxane
- calaspargase pegol
- temsirolimus
- devimistat
- obinutuzumab
- paclitaxel
- ar-42
- idelalisib
- in111 anti-cd45 monoclonal antibody bc8
- Filgrastim
- methoxyamine
- morab-004
- sunitinib
- rp6530
- siplizumab
- bevacizumab
- tetanus-cmv fusion peptide vaccine
- pacritinib
- acetic acid
- volasertib
- vorinostat
- y90 anti-cd45 monoclonal antibody bc8
- cediranib
- obatoclax
- umbralisib
- otlertuzumab
- gamma-delta t cells
- nilotinib
- cemiplimab
- ptx-100
- +15 more
Organizations
Organization Involved with Phase 4 Indications (5)
Organization Involved with Phase 3 Indications (17)
- Seattle Genetics
- Eisai
- Millennium Pharmaceuticals
- Portola Pharmaceuticals
- Aarhus University
- German High-Grade Non-Hodgkin's Lymphoma Study Group
- French Innovative Leukemia Organisation
- The Lymphoma Academic Research Organisation
- Columbia University
- Nordic Lymphoma Group
- Peking University
- Southern Medical University
- University of Goettingen
- University of Grenoble
- People's Liberation Army of China
- Shijiazhuang Pharma Group (CSPC)
- Chinese Academy of Medical Sciences
Organization Involved with Phase 2 Indications (133)
- AbbVie
- Takeda
- Celgene
- Bristol-Myers Squibb
- Amgen
- Merck
- Aileron Therapeutics
- Genzyme
- Pfizer
- Asana BioSciences
- Bayer
- BeOne Medicines
- CerRx, Inc.
- HUYA Bioscience International
- Innate Pharma
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Karyopharm Therapeutics Inc
- Kura Oncology, Inc.
- Kyowa Hakko Kirin
- Nanjing NingQi Medicine Science and Technology Co., Ltd.
- Valerio
- Ortho Biotech, Inc.
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- Sorrento Therapeutics, Inc.
- Verastem, Inc.
- Yiling Pharmaceutical Inc.
- Affimed GmbH
- Otsuka
- Solasia Pharma K.K.
- National Institutes of Health (NIH)
- +103 more
Organization Involved with Phase 1 Indications (35)
- ADC Therapeutics SARL
- Aptevo Therapeutics
- Morphotek
- Novartis
- Arno Therapeutics
- Bio-Path Holdings, Inc.
- Rhizen Pharmaceuticals SA
- Chipscreen Biosciences, Ltd.
- Tessa Therapeutics
- TG Therapeutics, Inc.
- British Columbia Cancer Agency
- Huazhong University of Science and Technology
- University of Pennsylvania
- Canadian Cancer Trials Group
- Emory University
- Johns Hopkins University
- New York Medical College
- Seoul National University
- University of Leeds
- University of Southern California
- Boryung Pharmaceutical Company
- Rush University
- SCRI Development Innovations
- Saint John Regional Hospital
- University of Alabama, Birmingham
- National Comprehensive Cancer Network
- Synex Consulting Korea Ltd.
- Government of Singapore
- Antengene Corporation
- Shanghai YingLi Pharmaceutical Co. Ltd.
- +5 more
Organization Involved with Other Experimental Indications (2)